Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDUFA III Or Waxman/Hatch II?: Payors Urge Fix For Generic “Loopholes”

Executive Summary

General Motors is among payors urging Congress to address Waxman/Hatch "loophole" legislation as part of the FDA user fee reauthorization bill

You may also be interested in...



Medicaid Rebate Changes, Waxman/Hatch Hearings Urged By Governors

The National Governors Association is endorsing the Bush Administration's proposal to increase Medicaid rebates as an immediate fix to resolve the states' escalating Rx drug costs

Medicaid Rebate Changes, Waxman/Hatch Hearings Urged By Governors

The National Governors Association is endorsing the Bush Administration's proposal to increase Medicaid rebates as an immediate fix to resolve the states' escalating Rx drug costs

FDA Budget Includes 61% PDUFA Increase; Agency Wants Proposal By May

FDA aims to reach an agreement with industry on the framework for reauthorization of the Prescription Drug User Fee Act by May, Acting Senior Associate Commissioner for Management & Systems Jeff Weber said Feb. 5 during a press briefing on the FDA budget

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS039187

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel